Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies
BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the…
2,230$
1,83%
Echtzeit-Aktienkurs Paratek Pharmaceuticals Inc,
Bid:
Ask:
Nachrichten zur Paratek Pharmaceuticals Inc, Aktie
Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference
BOSTON, May 16, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the…